Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution

Annals of Hematology

Volumn 89, Issue 6, 2010, Pages 545-551

  Bernasconi, Paolo ^a   Klersy, Catherine ^b   Boni, Marina ^a   Cavigliano, Paola Maria ^a   Giardini, Ilaria ^a   Rocca, Barbara ^a   Zappatore, Rita ^a   Dambruoso, Irene ^a   Calvello, Celeste ^a   Caresana, Marilena ^a   Lazzarino, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Cytogenetics; Myelodysplastic syndromes; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; DIFFERENTIATION INDUCING FACTOR; HEMOPOIETIC GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD TRANSFUSION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME Q BAND; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; TRISOMY 8; WORLD HEALTH ORGANIZATION; CELL TRANSFORMATION; EVALUATION; GENETICS; MIDDLE AGED; MOLECULAR EVOLUTION; MORTALITY; STATISTICS; SURVIVAL;

AGED; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; EVOLUTION, MOLECULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 77951644972     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0927-z     Document Type: Article

References (44)

1. ML Heaney DW Golde 1999 Myelodysplasia N Engl J Med 340 1649 1660 10.1056/NEJM199905273402107 1:STN:280:DyaK1M3ltF2nug%3D%3D 10341278 (Pubitemid 29249435)
2. SD Nimer 2008 Myelodysplastic syndromes Blood 11 4841 4851 10.1182/blood-2007-08-078139
3. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2008) Tumours of haematopoietic and lymphoid tissues. World health organization classification of tumours. IARC, Lyon
4. U Germing N Gattermann C Strupp M Aivado C Aul 2000 Validation of the WHO proposal for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients Leuk Res 24 983 992 10.1016/S0145- 2126(00)00088-6 1:STN:280:DC%2BD3M%2FltVyhug%3D%3D 11077111
5. T Nösslinger R Reisner E Koller H Grüner H Tüchler H Nowotny, et al. 2001 Myelodysplastic syndromes, from the French-American-British to world health organization: comparison of classifications on 431 unselected patients from a single institution Blood 98 2935 2941 10.1182/blood.V98.10.2935 11698274
6. J-H Lee J-H Lee J-R Shin W-K Kim H-S Chi C-J Park, et al. 2003 Application of different prognostic scoring systems and comparison of the FAB and WHO classification in Korean patients with myelodysplastic syndromes Leukemia 17 305 313 10.1038/sj.leu.2402798 12592327 (Pubitemid 36266905)
7. B Howe A Porwit-MacDonald R Wanat R Tehranchi E Hellström-Lindberg 2004 The WHO classification of MDS does make a difference Blood 103 3265 3270 10.1182/blood-2003-06-2124 1:CAS:528:DC%2BD2cXjslKgsL0%3D 14684416 (Pubitemid 38525649)
8. L Malcovati MG Della Porta C Pascutto R Invernizzi M Boni E Travaglino, et al. 2005 Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 7594 7603 10.1200/JCO.2005.01.7038 16186598 (Pubitemid 46291823)
9. C Strupp N Gattermann A Giagounidis C Aul B Hildebrandt R Haas U Germing 2003 Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals Leuk Res 27 397 404 10.1016/S0145-2126(02)00220-5 12620291 (Pubitemid 36287201)
10. U Germing C Strupp A Kuendgen M Aivado A Giagounidis B Hildebrandt, et al. 2006 Refractory anemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals B J Haematol 132 162 167 10.1111/j.1365-2141.2005.05853.x (Pubitemid 43381550)
11. U Germing C Strupp A Kuendgen S Isa S Knipp B Hildebrandt, et al. 2006 Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes Haematologica 91 1596 1604 17145595
12. P Valent HP Horny JM Bennet C Fonatsch U Germing P Greenberg, et al. 2007 Definitions and standards in the diagnosis and treatments of the myelodysplastic syndromes: consensus statements and report from a working conference Leuk Res 31 727 736 10.1016/j.leukres.2006.11.009 17257673 (Pubitemid 46855901)
13. GJ Mufti JM Bennet J Goasguen BJ Bain I Baumann R Brunning, et al. 2008 Diagnosis and classification of myelodysplastic syndromes: international working group on morphology of myelodysplastic syndrome Haematologica 93 1712 1717 10.3324/haematol.13405 18838480
14. M Breccia R Latagliata L Cannella I Carmosino R De Cuia A Frustaci, et al. 2009 Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal Leuk Res 33 391 394 10.1016/j.leukres.2008.06.033 1:CAS:528:DC%2BD1MXhtVCru7k%3D 18676015
15. M Jädersten E Hellström-Lindberg 2008 Myelodysplastic syndromes: biology and treatment J Int Med 265 307 328 10.1111/j.1365-2796.2008. 02052.x
16. M Cazzola L Malcovati 2005 Myelodysplastic syndromes - coping with ineffective hematopoiesis N Engl J Med 352 536 538 10.1056/NEJMp048266 1:CAS:528:DC%2BD2MXhtFemsr0%3D 15703418 (Pubitemid 40204666)
17. SJ Corey MD Minden DL Barber H Kantarjian JCY Wang AD Schimmer 2007 Myelodysplastic syndromes: the complexity of stem-cell diseases Nature Rev Cancer 7 118 129 10.1038/nrc2047 1:CAS:528:DC%2BD2sXotFOjtw%3D%3D (Pubitemid 46164747)
18. P Greenberg C Cox MM Le Beau P Fenaux P Morel G Sanz, et al. 1987 International system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079 2088
19. F Solè B Espinet G Sanz J Cervera MJ Calasanz E Luňo, et al. 2000 Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes B J Haematol 108 346 356 10.1046/j.1365-2141.2000.01868.x (Pubitemid 30143651)
20. F Solè E Luňo C Sanzo B Espinet GF Sanz J Cervera, et al. 2005 Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes Haematologica 90 1168 1178 16154839
21. P Bernasconi C Klersy M Boni PM Cavigliano I Giardini B Rocca, et al. 2005 Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplatic syndromes: a study on 331 patients from a single institution Leukemia 19 1424 1431 10.1038/sj.leu.2403806 1:CAS:528: DC%2BD2MXmt12qu7Y%3D 15920496 (Pubitemid 41136337)
22. P Bernasconi C Klersy M Boni PM Cavigliano S Calatroni I Giardini, et al. 2007 World health organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes B J Haematol 137 193 205 10.1111/j.1365-2141.2007. 06537.x 1:CAS:528:DC%2BD2sXmtVGrsbs%3D (Pubitemid 46537628)
23. D Haase U Germing J Schanz M Pfeilstöcker T Nösslinger B Hildebrandt, et al. 2007 New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core data set of 2124 patients Blood 110 4385 4395 10.1182/blood-2007-03-082404 1:CAS:528:DC%2BD1cXot1Sq 17726160 (Pubitemid 351377805)
24. L Malcovati U Germing A Kuendgen MG Della Porta C Pascutto R Invernizzi, et al. 2007 Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 3503 3510 10.1200/JCO.2006.08.5696 17687155 (Pubitemid 47315575)
25. HJ Olney MM Le Beau 2001 The cytogenetics of myelodysplastic syndromes Best Pract Res Clin Hematol 14 479 495 10.1053/beha.2001.0151 1:CAS:528:DC%2BD38Xhs1Onsw%3D%3D (Pubitemid 33019747)
26. P Bernasconi M Boni PM Cavigliano S Calatroni I Giardini B Rocca, et al. 2006 Clinical relevance of cytogenetics in myelodysplastic syndromes Ann NY Acad Sci 1089 395 410 10.1196/annals.1386.034 17261783 (Pubitemid 47092089)
27. G Tricot MA Boogaerts C de Wolf-Peeters H Van den Berghe RL Verwilghen 1985 The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations B J Haematol 59 659 670 10.1111/j.1365-2141.1985.tb07361.x 1:STN:280:DyaL2M7nsFSiug%3D%3D
28. J Benitez F Carbonell J Sanchez Fayos H Heimpel 1985 Karyotypic evolution in patients with myelodysplastic syndromes Cancer Gen Cytogen 15 157 167 10.1016/0165-4608(85)90010-X (Pubitemid 15103539)
29. S Horiike M Taniwaki S Misawa T Abe 1988 Chromosome abnormalities and karyotype evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis Cancer 62 1129 1138 10.1002/1097-0142(19880915)62:6<1129: :AID-CNCR2820620616>3.0.CO;2-C 1:STN:280:DyaL1czhtVOlsg%3D%3D 3409186
30. S Suciu R Kuse HJ Weh DK Hossfeld 1990 Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome Cancer Gen Cytogen 44 15 26 10.1016/0165-4608(90) 90193-E 1:STN:280:DyaK3c%2FptVChtw%3D%3D (Pubitemid 20039179)
31. K Michalova J Musilova Z Zemanova 1991 Consecutive chromosomal studies in patients with myelodysplastic syndrome (MDS). Czechoslovak MDS Cooperative Group Ann Genet 34 212 218 1:STN:280:DyaK383jtFCruw%3D%3D 1809229
32. AD White DJ Culligan TG Hoy A Jacobs 1992 Extended cytogenetic follow-up of patients with myelodysplastic syndrome (MDS) B J Haematol 81 499 502 10.1111/j.1365-2141.1992.tb02981.x 1:STN:280:DyaK3s%2Fgt1Cltg%3D%3D
33. HM Ghaddar SA Stass S Pierce EH Estey 1994 Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukaemia: implications on the overlap between the two diseases Leukemia 8 1649 1653 1:STN:280:DyaK2M%2FhvFyjtw%3D%3D 7934160
34. AD White TG Hoy A Jacobs 1994 Extended cytogenetic follow-up and clinical progress in patients with myelodysplastic syndromes (MDS) Leuk Lymph 12 401 412 10.3109/10428199409073781 1:STN:280:DyaK2c3js1Wgsw%3D%3D
35. HF Tien CH Wang SM Chuang FY Lee MC Liu YC Chen, et al. 1995 Acute leukaemic transformation of myelodysplastic syndrome-immunophenotypic, genotypic, and cytogenetic studies Leuk Res 19 595 603 10.1016/0145-2126(95) 00015-G 1:STN:280:DyaK28%2FjtlSktw%3D%3D 7564469
36. FT De Souza MH Ornellas LO de Carvalho D Tabak E Abdelhay 2000 Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukaemia Leuk Res 24 839 848 10.1016/S0145-2126(00)00056-4
37. Mitelman F. (ed) (1995) ISCN: an international system for human cytogenetic nomenclature. Karger, Basel
38. B Novotna R Neuwirtova M Siskova Y Bagryantseva 2008 DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts Hum Mol Genet 17 2144 2149 10.1093/hmg/ddn113 1:CAS:528: DC%2BD1cXnvV2qtrs%3D 18430715 (Pubitemid 351911983)
39. P Bernasconi 2008 Molecular pathways in myelodysplastic syndromes and acute myeloid leukaemia: relationship and distinctions-a review Brit J Haematol 142 695 708 10.1111/j.1365-2141.2008.07245.x 1:CAS:528:DC%2BD1cXhtFWntrrM
40. C Pomeroy MM Oken RE Rydell GA Filice 1991 Infection in the myelodysplastic syndromes Am J Med 90 338 344 1:STN:280:DyaK3M7msFyntg%3D%3D 2003516
41. H Kantarjian F Giles A List R Lyons MA Sekeres S Pierce, et al. 2007 The incidence and impact of thrombocytopenia in myelodysplastic syndromes Cancer 109 1705 1714 10.1002/cncr.22602 1:CAS:528:DC%2BD2sXlsF2ntbw%3D 17366593 (Pubitemid 46668530)
42. U Germing B Hildebrandt M Pfeilstöcker T Nösslinger P Valent C Fonatsch, et al. 2005 Refinement of the International Prognostic Scoring System (IPSS) by including LDH as an additional scoring variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) Leukemia 19 2223 2231 10.1038/sj.leu.2403963 1:CAS:528:DC%2BD2MXht1ems7nE 16193087 (Pubitemid 41741618)
43. JM Kao A McMillan P Greenberg 2008 International MDs risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes Am J Hematol 83 765 770 10.1002/ajh.21249 1:CAS:528:DC%2BD1cXhtlSgtrjF 18645988
44. DT Starczynowski S Vercauteren A Telenius S Sung K Tohyama A Brooks-Wilson, et al. 2008 High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival Blood 112 3412 3424 10.1182/blood-2007-11-122028 1:CAS:528: DC%2BD1cXht1OmurrN 18663149